Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States
- PMID: 36736715
- PMCID: PMC10759792
- DOI: 10.1016/j.contraception.2023.109962
Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States
Abstract
Objective: Given the substantial barriers to abortion access in the United States, many clinics now mail patients abortion medications. We examined whether dispensing the medications by mail prolonged time to medication use.
Study design: We analyzed data from no-test medication abortions with medication provided either by mail or in a clinic from 11 United States clinics from February 2020 to January 2021. We examined mean number of days from patients' first contact with the clinic to mifepristone ingestion, its two-component intervals (first contact to medication dispensing and dispensing to mifepristone ingestion), and pregnancy duration at mifepristone ingestion. We used Poisson regression to compare mean outcomes across three dispensing methods: in-person, mailed from the clinic, and mailed from a mail-order pharmacy.
Results: Among the 2600 records, patients took mifepristone on average at 49 days of gestation (95% CI, 47-51) and 7 days (95% CI, 4-10) after first contact. Mean time from first contact to mifepristone ingestion was 6 days when medications were dispensed in-person and 9 days when mailed (p = 0.38). While time from first contact to dispensing was similar across methods (6 days in-person, 5 days mailed, p = 0.77), more time elapsed from dispensing to mifepristone ingestion when medications were mailed (4 days from clinic, 5 days from mail-order pharmacy) versus dispensed in-person (0.3 days, p < 0.001). Time to mifepristone ingestion was shorter with higher pregnancy duration. Pregnancy duration at ingestion was similar across methods (48 days in-person, 50 days mailed).
Conclusions: Mailing medications did not significantly prolong time from patients' first contact with the clinic to mifepristone ingestion or increase pregnancy duration at mifepristone ingestion.
Implications: Abortion providers should offer a range of medication abortion dispensing options, prioritizing patient preference.
Keywords: Mailing; Medication abortion; Mifepristone; Pharmacy; Risk Evaluation and Mitigation Strategy (REMS); Telehealth.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Figures


Similar articles
-
Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening.JAMA Intern Med. 2024 Aug 1;184(8):873-881. doi: 10.1001/jamainternmed.2024.1476. JAMA Intern Med. 2024. PMID: 38739404 Free PMC article.
-
Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment.Contraception. 2022 Mar;107:36-41. doi: 10.1016/j.contraception.2021.09.008. Epub 2021 Sep 20. Contraception. 2022. PMID: 34555420
-
Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study.JAMA Intern Med. 2022 May 1;182(5):482-491. doi: 10.1001/jamainternmed.2022.0217. JAMA Intern Med. 2022. PMID: 35311911 Free PMC article.
-
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review.Contraception. 2022 Nov;115:62-66. doi: 10.1016/j.contraception.2022.06.012. Epub 2022 Jun 28. Contraception. 2022. PMID: 35772525 Review.
-
Abortion in Primary Care.Prim Care. 2025 Jun;52(2):277-290. doi: 10.1016/j.pop.2025.01.002. Epub 2025 Apr 1. Prim Care. 2025. PMID: 40412906 Review.
Cited by
-
Effectiveness and safety of telehealth medication abortion in the USA.Nat Med. 2024 Apr;30(4):1191-1198. doi: 10.1038/s41591-024-02834-w. Epub 2024 Feb 15. Nat Med. 2024. PMID: 38361123 Free PMC article.
-
Differences in Abortion Use by Sexual Orientation in 3 National Cohorts.JAMA Netw Open. 2025 May 1;8(5):e258644. doi: 10.1001/jamanetworkopen.2025.8644. JAMA Netw Open. 2025. PMID: 40327342 Free PMC article.
References
-
- Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug Admin. No. 472 F. Supp. 3d 183 (United States District Court of Maryland; 2020).
-
- US Food and Drug Administration. Mifeprex Risk Evaluation and Mitigation Strategy (REMS) Program. US Food and Drug Administration; 2023.